Physician profile
Ewa Rakowski
NPI 1528356979
$2,832.94
in general payments reported to CMS, 2019-2025
22 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $1,304 · 2021: $29.62 · 2022: $167 · 2023: $175 · 2024: $245 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,400.65 | 2020-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $543.98 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $169.04 | 2019-2023 | Zerbaxa, Dificid, Recarbrio |
| Advanced Respiratory, INC | $85.38 | 2019 | |
| Genzyme Corporation | $84.40 | 2022-2024 | |
| United Therapeutics Corporation | $69.30 | 2023-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $60.14 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.30 | 2024-2025 | Ofev, Jascayd |
| Chiesi USA, INC. | $43.86 | 2021-2022 | |
| Astellas Pharma US INC | $36.39 | 2019 | |
| Verona Pharma, INC. | $34.03 | 2025 | Ohtuvayre |
| Amgen INC. | $33.71 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $31.22 | 2024 | Uptravi, Opsumit |
| Shionogi INC | $24.67 | 2022 | |
| Grifols USA, LLC | $24.29 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.03 | 2020 | |
| Olympus America INC. | $21.27 | 2019 | |
| Philips North America LLC | $20.82 | 2025 | Vest Therapy Und |
| Mylan Specialty L.P. | $20.51 | 2024 | Yupelri |
| Harmony Biosciences LLC | $18.10 | 2024 | |
| Axsome Therapeutics, INC. | $17.74 | 2025 | Sunosi |
| Genentech USA, INC. | $17.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ewa Rakowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.